uploads///Internal Medicine

How Has Pfizer’s Internal Medicine Portfolio Performed in 2017?

By

Nov. 30 2017, Updated 10:31 a.m. ET

Lyrica revenue trends

In 3Q17, Pfizer’s (PFE) Lyrica reported revenues of $1.3 billion, which is ~4% growth on a year-over-year (or YoY) basis and 2% growth on a quarter-over-quarter basis. During the first nine months of 2017, Lyrica reported revenues of $3.8 billion, which reflected ~2% growth on a YoY basis. Lyrica generated revenues of $2.6 billion and $1.2 billion, respectively, during the first nine months of 2017 from the US market and international markets, respectively.

In October 2017, the Food and Drug Administration (or FDA) approved Lyrica CR extended-release tablets for the treatment of neuropathic pain related to diabetic peripheral neuropathy and the treatment of postherpetic neuralgia.

Article continues below advertisement

Viagra revenue trends

In 3Q17, Viagra generated revenues of $308 million, a ~20% decline on a YoY basis and a 12% decline on a quarter-over-quarter basis. Viagra reported year-to-date September 2017 revenues of $996 million, a ~16% decline on a YoY basis. In the US and international markets, Viagra reported revenues of $687 million and $309 million in the first nine months of 2017, respectively, which is a ~21% and 1% decline on a YoY basis.

Viagra’s competitors include Bayer’s (BAYZF) Staxyn and Levitra and Eli Lilly’s (LLY) Cialis. The Pharmaceuticals ETF (PPH) invests ~5.2% and 4.6% of its total portfolio holdings in Pfizer and Eli Lilly, respectively.

Chantix/Champix revenue trends

In 3Q17, Chantix/Champix generated revenues of $240 million, which is ~21% growth on a YoY basis and a 3% decline on a quarter-over-quarter basis. Chantix/Champix reported revenues for the first nine months of 2017 of $727 million, which is ~15% growth on a YoY basis. In the US and international markets, Chantix/Champix reported revenues of $542 million and $184 million, respectively, in the first nine months of 2017 compared to revenues of $449 million and $182 million in the first nine months of 2016.

Article continues below advertisement

Toviaz revenue trends

In 3Q17, Toviaz generated revenues of $62 million, which is ~3% growth on a YoY basis. Pfizer’s Toviaz reported YTD September 2017 revenues of $187 million, which is ~2% growth on a YoY basis. In the US and international markets, Toviaz reported revenues of $63 million and $124 million, respectively, in the first nine months of 2017 compared to $72 million and $119 million in the first nine months of 2016. Toviaz’s competitors include Allergan’s (AGN) Enablex.

BMP2 revenue trends

In 3Q17, BMP2 (Bone Morphogenetic Protein 2) generated revenues of $79 million, which is ~25% growth on a YoY basis and 39% growth on a quarter-over-quarter basis. Pfizer’s BMP2 reported revenues for the first nine months of 2017 of $198 million, a ~13% increase on a YoY basis.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.